Pharmacological and expression profile of the prostaglandin I 2 receptor in the rat craniovascular system

Vascular Pharmacology

Volumn 55, Issue 1-3, 2011, Pages 50-58

  Myren, Maja ^a   Olesen, Jes ^a   Gupta, Saurabh ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Craniovascular system; IP receptor; Migraine; PGI2; PGI2 receptor antagonist

Indexed keywords

CAY 10441; ILOPROST; MESSENGER RNA; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; RO 1138452; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BASILAR ARTERY; BRAIN ARTERY; DOSE RESPONSE; DRUG EFFECT; IN VIVO STUDY; MENINGEAL ARTERY; MIDDLE MENINGEAL ARTERY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

ANIMALS; BENZYL COMPOUNDS; CEREBRAL ARTERIES; EPOPROSTENOL; ILOPROST; IMIDAZOLES; MALE; MENINGEAL ARTERIES; MUSCLE, SMOOTH, VASCULAR; NOCICEPTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, EPOPROSTENOL; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; VASODILATION; VASODILATOR AGENTS;

EID: 80051791577     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.06.004     Document Type: Article

References (34)

1. Abramovitz M., Adam M., Boie Y., Carriere M., Denis D., Godbout C., Lamontagne S., Rochette C., Sawyer N., Tremblay N.M., Belley M., Gallant M., Dufresne C., Gareau Y., Ruel R., Juteau H., Labelle M., Ouimet N., Metters K.M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta 2000, 1483:285-293.
2. Abramovitz M., Breyer R.M., Coleman R.A., Hills R., Jones R.L., Narumiya S., Woodward D.F. Prostanoid receptors: IP1.IUPHAR database (Last accessed June 8, 2011). http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?familyId=58&objectId=345.
3. Armstead W.M. Role of nitric oxide and cAMP in prostaglandin-induced pial arterial vasodilation. Am. J. Physiol. 1995, 268:H1436-H1440.
4. Bley K.R., Bhattacharya A., Daniels D.V., Gever J., Jahangir A., O'Yang C., Smith S., Srinivasan D., Ford A.P., Jett M.F. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br. J. Pharmacol. 2006, 147:335-345.
5. Boie Y., Rushmore T.H., Darmon-Goodwin A., Grygorczyk R., Slipetz D.M., Metters K.M., Abramovitz M. Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem. 1994, 269:12173-12178.
6. Boie Y., Stocco R., Sawyer N., Slipetz D.M., Ungrin M.D., Neuschafer-Rube F., Puschel G.P., Metters K.M., Abramovitz M. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur. J. Pharmacol. 1997, 340:227-241.
7. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 2000, 343(1520-8):2. VIGOR Study Group.
8. Boullin D.J., Bunting S., Blaso W.P., Hunt T.M., Moncada S. Responses of human and baboon arteries to prostaglandin endoperoxides and biologically generated and synthetic prostacyclin: their relevance to cerebral arterial spasm in man. Br. J. Clin. Pharmacol. 1979, 7:139-147.
9. Brennan K.C., Charles A. An update on the blood vessel in migraine. Curr. Opin. Neurol. 2010, 23:266-274.
10. Chan K.Y., Vermeersch S., de Hoon J., Villalon C.M., Maassenvandenbrink A. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Pharmacol. Ther. 2011, 129:332-351.
11. Clark R.D., Jahangir A., Severance D., Salazar R., Chang T., Chang D., Jett M.F., Smith S., Bley K. Discovery and SAR development of 2-(phenylamino) imidazolines as prostacyclin receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14:1053-1056. [corrected].
12. Davis R.J., Murdoch C.E., Ali M., Purbrick S., Ravid R., Baxter G.S., Tilford N., Sheldrick R.L., Clark K.L., Coleman R.A. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br. J. Pharmacol. 2004, 141:580-585.
13. Gupta S., Bhatt D., Boni L., Olesen J. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia 2010, 30:27-36.
14. Hingtgen C.M., Waite K.J., Vasko M.R. Prostaglandins facilitate peptide release from rat sensory neurons by activating the adenosine 3′,5′-cyclic monophosphate transduction cascade. J. Neurosci. 1995, 15:5411-5419.
15. Höcherl K., Schmidt C., Kurt B., Bucher M. Activation of the PGI2/IP system contributes to the development of circulatory failure in a rat model of endotoxic shock. Hypertension 2008, 52:330-335.
16. Hogestatt E.D., Uski T.K. Actions of some prostaglandins and leukotrienes on rat cerebral and mesenteric arteries. Gen. Pharmacol. 1987, 18:111-117.
17. Jenkins D.W., Feniuk W., Humphrey P.P. Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br. J. Pharmacol. 2001, 134:1296-1302.
18. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 1997, 122:217-224.
19. Lassen L.H., Haderslev P.A., Jacobsen V.B., Iversen H.K., Sperling B., Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002, 22:54-61.
20. Levy D., Strassman A.M. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J. Physiol. 2002, 538:483-493.
21. Maubach K.A., Davis R.J., Clark D.E., Fenton G., Lockey P.M., Clark K.L., Oxford A.W., Hagan R.M., Routledge C., Coleman R.A. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br. J. Pharmacol. 2009, 156:316-327.
22. Merritt J.E., Brown A.M., Bund S., Cooper D.G., Egan J.W., Hallam T.J., Heagerty A.M., Hickey D.M., Kaumann A.J., Keen M. Primate vascular responses to octimibate, a non-prostanoid agonist at the prostacyclin receptor. Br. J. Pharmacol. 1991, 102:260-266.
23. Mitchell J.A., Ali F., Bailey L., Moreno L., Harrington L.S. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp. Physiol. 2008, 93:141-147.
24. Myren M., Baun M., Ploug K.B., Jansen-Olesen I., Olesen J., Gupta S. Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine. Cephalalgia 2010, 30:1110-1122.
25. Oida H., Namba T., Sugimoto Y., Ushikubi F., Ohishi H., Ichikawa A., Narumiya S. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br. J. Pharmacol. 1995, 116:2828-2837.
26. Petersen K.A., Dyrby L., Williamson D., Edvinsson L., Olesen J. Effect of hypotension and carbon dioxide changes in an improved genuine closed cranial window rat model. Cephalalgia 2005, 25:23-29.
27. Sarchielli P., Alberti A., Codini M., Floridi A., Gallai V. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000, 20:907-918.
28. Stitham J., Arehart E.J., Gleim S.R., Douville K.L., Hwa J. Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations. Prostaglandins Other Lipid Mediators 2007, 82:95-108.
29. Whalley E.T., Schilling L., Wahl M. Cerebrovascular effects of prostanoids: in-vitro studies in feline middle cerebral and basilar artery. Prostaglandins 1989, 38:625-634.
30. Wienecke T., Olesen J., Oturai P.S., Ashina M. Prostacyclin (epoprostenol) induces headache in healthy subjects. Pain 2008, 139:106-116.
31. Wienecke T., Olesen J., Ashina M. Prostaglandin I(2) (epoprostenol) triggers migraine-like attacks in migraineurs. Cephalalgia 2010, 30:179-190.
32. Wolfe M.M., Lichtenstein D.R., Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999, 340:1888-1899.
33. Zeilhofer H.U. Prostanoids in nociception and pain. Biochem. Pharmacol. 2007, 73:165-174.
34. Zhang X.C., Strassman A.M., Burstein R., Levy D. Sensitization and activation of intracranial meningeal nociceptors by mast cell mediators. J. Pharmacol. Exp. Ther. 2007, 322:806-812.